Andrew Hordes, MD
Cardiovascular Disease · Pawtucket, RINPI 1174583595
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,024 of the $6,926 with a category attached, or 72.5%. 33 manufacturers reported payments, led by Medtronic at 55.2% of the total. Reporting peaked in 2019 at $3,098 and has fallen 88.6% since, to $352 in 2025. Among cardiovascular disease clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 243 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Amgen$434
- Johnson & Johnson$394
- Pfizer$342
- AstraZeneca$305
- Boston Scientific$188
- plus $1K from 27 others
Across 3 payments — averaging $475.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$1K
What the payments were for
- Travel & lodging$1,54922%
- Food & beverage$5,02473%
- Education$3535%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 62 | $3,820 |
| Amgen | 28 | $434 |
| Johnson & Johnson | 44 | $394 |
| Pfizer | 19 | $342 |
| AstraZeneca | 16 | $305 |
| Boston Scientific | 7 | $188 |
| Actelion Pharmaceuticals US, Inc. | 7 | $186 |
| Novartis | 9 | $152 |
| Scpharmaceuticals Inc. | 4 | $116 |
| Impulse Dynamics (USA) Inc. | 1 | $106 |
| Merck | 4 | $93 |
| Novo Nordisk | 5 | $89 |
| Boehringer Ingelheim | 5 | $89 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| GE HealthCare | 1 | $52 |
| Amarin Pharma, Inc. | 3 | $51 |
| Irhythm Technologies, Inc. | 3 | $49 |
| Biosense Webster, Inc. | 1 | $45 |
| Baxter Healthcare | 2 | $37 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $26 |
| Lundbeck LLC | 1 | $23 |
| Elutia, Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $23 |
| Abiomed | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Edwards Lifesciences | 1 | $17 |
| Infobionic, Inc | 1 | $15 |
| Abbott | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Claria MRI$202
- Azure$145
- Micra$143
- COBALT DR MRI SURESCAN$109
- OPTIMIZER SMART SYSTEM$106
How this compares
$6,926 in reported general payments places this provider in the 90th percentile of 86 cardiovascular disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 453 | $542,399 |
| XareltoRivaroxaban | 85 | $109,994 |
| EntrestoSacubitril/Valsartan | 88 | $96,929 |
| JardianceEmpagliflozin | 44 | $47,419 |
| Repatha SureclickEvolocumab | 28 | $27,523 |
| Dofetilide | 31 | $7,137 |
| Metoprolol Succinate | 423 | $5,988 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 182 | $4,767 |
| Propafenone Hcl ErPropafenone Hcl | 25 | $4,613 |
| Carvedilol ErCarvedilol Phosphate | 12 | $3,868 |
| Atorvastatin Calcium | 274 | $2,898 |
| Losartan Potassium | 265 | $2,543 |
| Valsartan | 79 | $2,106 |
| Rosuvastatin Calcium | 218 | $2,050 |
| Ezetimibe | 96 | $1,766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $342 | $542,399453 claims |
| Johnson & JohnsonXarelto | $394 | $109,99485 claims |
| NovartisEntresto | $152 | $96,92988 claims |
| Boehringer IngelheimJardiance | $89 | $47,41944 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 86 cardiovascular disease providers in Rhode Island.
Other cardiovascular disease in Pawtucket
- Thomas NoonanPawtucket$223
- Ibrahim ElgabryWoonsocket$72K
- Ara SadaniantzProvidence$27K
- George BourganosWoonsocket$16K
- Edward ThomasWarwick$15K
- John CavaProvidence$12K
- Jeremy LumProvidence$10K
- Franklin SchneiderProvidence$8K
- Andrew ThorpLincoln$8K
- Gisele SalibaProvidence$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.